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Protein glycosylation events that happen early in the secretory
pathway are often dysregulated during tumorigenesis. These
events can be probed, in principle, by monosaccharides with
bioorthogonal tags that would ideally be specific for distinct
glycan subtypes. However, metabolic interconversion into other
monosaccharides drastically reduces such specificity in the living
cell. Here, we use a structure-based design process to develop
the monosaccharide probe N-(S)-azidopropionylgalactosamine
(GalNAzMe) that is specific for cancer-relevant Ser/Thr(O)–linked
N-acetylgalactosamine (GalNAc) glycosylation. By virtue of a branched
N-acylamide side chain, GalNAzMe is not interconverted by epimeri-
zation to the corresponding N-acetylglucosamine analog by the epim-
erase N-acetylgalactosamine–4-epimerase (GALE) like conventional
GalNAc–based probes. GalNAzMe enters O-GalNAc glycosylation
but does not enter other major cell surface glycan types including
Asn(N)-linked glycans. We transfect cells with the engineered
pyrophosphorylase mut-AGX1 to biosynthesize the nucleotide-
sugar donor uridine diphosphate (UDP)-GalNAzMe from a sugar-
1-phosphate precursor. Tagged with a bioorthogonal azide group,
GalNAzMe serves as an O-glycan–specific reporter in superresolu-
tion microscopy, chemical glycoproteomics, a genome-wide CRISPR-
knockout (CRISPR-KO) screen, and imaging of intestinal organoids.
Additional ectopic expression of an engineered glycosyltransferase,
“bump-and-hole” (BH)–GalNAc-T2, boosts labeling in a programma-
ble fashion by increasing incorporation of GalNAzMe into the cell
surface glycoproteome. Alleviating the need for GALE-KO cells in
metabolic labeling experiments, GalNAzMe is a precision tool that
allows a detailed view into the biology of a major type of cancer-
relevant protein glycosylation.
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The many facets of cellular glycosylation in health and diseasedemand methods of visualizing and characterizing glyco-
conjugates. These methods are essential for the development of
next-generation therapeutics and diagnostics that depend on
understanding glycosylation of target biomolecules (1, 2). A number
of modern experimental techniques have shaped our understanding
of biology, such as advanced microscopy, mass spectrometry (MS)
(glyco-)proteomics, and genome-wide CRISPR-knockout (CRISP-
R-KO) screens. Application of these techniques to glycobiology
relies on the suitability of detection reagents. Antibodies, lectins,
and engineered hydrolases have been instrumental but are some-
what restricted to sterically accessible epitopes (3–7). Monosac-
charides with bioorthogonal, chemically editable functionalities
have allowed a complementary view into glycobiology by entering
early glycosylation events (8–12). For instance, the first azide-
containing N-acetylgalactosamine (GalNAc) analog, GalNAz, and
subsequent renditions made it possible to probe core glycosylation
that is difficult to reach with protein-based reagents (9). GalNAc
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analogs are fed to cells as esterase-sensitive precursors and con-
verted into the corresponding uridine diphosphate (UDP) sugar
donors by the kinase GALK2 and the pyrophosphorylase AGX1
(Fig. 1A). The cellular glycosylation machinery then incorporates
tagged monosaccharides into glycoconjugates where they are reac-
ted with reporter moieties such as fluorophores or biotin by either
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) or strain-
promoted azide-alkyne cycloaddition (SPAAC) (13, 14).
A particular drawback of most current chemically modified
monosaccharides is their low specificity: UDP-GalNAz enters
mucin-type (Ser/Thr–N-acetylgalactosamine [O-GalNAc]) glycans
but is also converted to the corresponding GlcNAc derivative UDP-
GlcNAz by the cellular UDP-GlcNAc/N-acetylgalactosamine–4-
epimerase (GALE) (Fig. 1A) (15). UDP-GlcNAz then enters
N-linked glycans as well as other GlcNAc-containing glycans (15,
16). Other GalNAc analogs are presumably interconverted into
GlcNAc analogs in a similar fashion, but their metabolic fate can be
variable (17).
Forays have been made into developing reagents that are
specific for the structurally simple nucleocytoplasmic O-GlcNAc
modification (18–20). However, no such reagents are available to
specifically probe the complex cell surface O-GalNAc glycosyl-
ation that has fundamental relevance in many aspects of cancer
(21, 22).
Studying O-GalNAc glycoproteins by MS-based glyco-
proteomics is complicated by glycan heterogeneity, the lack of
O-glycosylation consensus sequences, and selective enrichment
tools. Further complexity is added by the interplay of 20 GalNAc
transferase (GalNAc-T1. . .-T20) isoenzymes that mediate the
first O-GalNAc biosynthesis step (23, 24). In a “bump-and-hole”
(BH) approach, we have recently engineered GalNAc-Ts to
carry a double mutation to preferentially accept UDP-GalNAc
analogs with bulky chemical, editable tags (25, 26). Although this
technique produced bioorthogonal reporters with great speci-
ficity for particular GalNAc-T isoenzymes, epimerization of
GalNAc analogs by GALE was still a challenge and resulted in
background N-glycan labeling (26).
A strategy to visualize O-GalNAc glycans based on metabolic
labeling is the use of GalNAz in GALE-deficient cells that
cannot epimerize UDP-GalNAz (15, 27). However, this strategy
is of limited use as GALE deficiency heavily interferes with
glycan metabolism and might therefore not be easily adaptable
to multicellular model systems such as organoids (28, 29).
Here, we report the GalNAc-specific bioorthogonal metabolic
labeling reagent N-(S)-azidopropionylgalactosamine (GalNAzMe).
Using a collection of synthetic azide-containing UDP-GalNAc analogs
and structure-informed probe design, we find that branched acylamide
side chains confer resistance to GALE-mediated epimerization and
therefore, eliminate the need of using N-acetylgalactosamine–4-
epimerase–knockout (GALE-KO) cells for metabolic labeling
experiments. We use a caged precursor of the nucleotide-sugar
UDP-GalNAzMe to probe O-GalNAc glycosylation in a range of
experimental conditions, including superresolution microscopy,
chemical MS glycoproteomics, a genome-wide CRISPR-KO screen,
and intestinal organoid imaging. GalNAzMe labeling can be en-
hanced in the presence of a BH-GalNAc-T2 double mutant, further
expanding the use of this monosaccharide in glycobiology experi-
ments. Precision tools such as GalNAzMe are essential to uncover
the fine details of cellular glycosylation.
Results
Probe Design. We envisioned that a chemically modified UDP-
GalNAc analog would be O-GalNAc specific if it was 1) not
epimerized to the UDP-GlcNAc analog by GALE and 2) used by
either wild-type (WT) or BH-engineered GalNAc-Ts to be in-
corporated into cell surface O-GalNAc glycans (Fig. 1A). In-
vestigation of the cocrystal structure of human GalNAc-T2 and
UDP-GalNAc suggested that the GalNAc acetamide group is
embedded in a pocket that allows for some three-dimensional
freedom (Fig. 1A). A similar binding site architecture was ob-
served in the crystal structures of GalNAc-T10 and GalNAc-T7
with GalNAc or UDP-GalNAc in their active sites, respectively
(SI Appendix, Fig. S1A) (30, 31). In contrast to GalNAc-Ts,
human GALE accommodates the acetamide in a long, narrow
cavity, as evidenced in a cocrystal structure of GALE with
Fig. 1. Design of an O-GalNAc–specific metabolic labeling reagent. (A) Rationale of probe design. UDP-GalNAc analogs that are not epimerized to the
corresponding UDP-GlcNAc derivatives are O-GalNAc specific by design. Derivatives are delivered to the living cell by virtue of per-acetylated or
phosphotriester-caged precursors. Compounds with a sterically congested diversification may be resistant to GALE-mediated epimerization but are accepted
by GalNAc-Ts. Inset shows UDP-GlcNAc and UDP-GalNAc binding by GalNAc-T2 and GALE, respectively. (B) In vitro epimerization as assessed by ion-pair HPLC.
Retention times of UDP-GalNAc analogs (yellow) and UDP-GlcNAc analogs (blue) are highlighted based on retention times of standards or epimerization
reactions with 50-fold higher GALE concentration (SI Appendix, Fig. S1B). Arrowhead depicts epimerization of compound 3. Numbers are percentage epi-
merization as assessed by peak integration as means ± SD of three independent replicates or not detected (n.d.). Traces depict relative intensity of absorbance
at 260 nm. Data are from one representative of three independent experiments and were reproduced using lysates of WT cells as a source of GALE or GALE-
KO cells as a negative control in two independent replicates (SI Appendix, Fig. S1B). ATP, adenosine triphosphate; PDB, protein database identifier.
































UDP-GlcNAc (Fig. 1A). This difference in substrate recognition
prompted us to explore the chemical determinants of GALE-
mediated epimerization by in vitro assays. We expressed hu-
man GALE in insect cells and used a collection of UDP-GalNAc
1 as well as analogs 2 to 10 with azide-containing acylamide
groups as substrates for epimerization (25, 32). Ion-pair high-
performance liquid chromatography (HPLC) was used to sepa-
rate the UDP-GalNAc analogs from their UDP-GlcNAc epimers
(33). UDP-GalNAc 1, UDP-GalNAz 2, and uridine diphosphate-
N-3-azidopropionate 3, which we term UDP-GalNPrAz, were
epimerized to the corresponding UDP-GlcNAc derivatives
(Fig. 1B). In contrast, all compounds containing a branched acy-
lamide moiety (4 to 10) were resistant toward epimerization under
these conditions, evident by the absence of a peak with a later
retention time in HPLC chromatograms. To rule out coelution of
both epimers, we used commercial and newly synthesized UDP-
GlcNAc–derived epimers of 1 (UDP-GlcNAc), 2 (UDP-GlcNAz),
3 (UDP-GlcNPrAz), and 5 (UDP-GlcNAzMe) as standards and
confirmed a marked difference in retention time (SI Appendix,
Fig. S1B). GALE-mediated epimerization of linear but not
branched UDP-GalNAc analogs was corroborated by performing
the reactions in the presence of cytosolic extracts of K-562 cells
with or without functional GALE (control single-guide RNA
[sgRNA] and GALE-KO, respectively) (26). An extract containing
GALE epimerized compounds 1 to 3, but not 4 to 10, whereas an
extract from GALE-KO cells was devoid of epimerization in all
cases (SI Appendix, Fig. S1C). When assessing the scope of GALE
reactivity, we succeeded in forcing branched analogs 4 to 9 to
epimerize by increasing the concentration of purified GALE
50-fold in vitro (SI Appendix, Fig. S1C). These data indicate that
branched acylamide side chains confer resistance to epimerization
unless the concentration of GALE is increased to unphysiologi-
cally high levels.
We then chose one of the structurally simplest branched UDP-
GalNAc analogs in our collection to assess turnover by GalNAc-
Ts. We had previously found UDP-GalNAzMe 5 to be a sub-
strate of WT-GalNAc-T2 (25) and confirmed acceptance by
WT-GalNAc-T1, -T7, and -T10 in in vitro glycosylation experi-
ments of peptide substrates (SI Appendix, Fig. S2A) (25). UDP-
GalNAzMe 5 displayed a very similar activity profile to the well-
known substrates UDP-GalNAc 1 and UDP-GalNAz 2, albeit at
lower incorporation levels. The azide-containing molecules 2 and
5 were used by WT-T1 and -T2 to glycosylate proteins in a
membrane protein preparation, as visualized by CuAAC with a
biotin-alkyne and fluorescently labeled streptavidin by western
blot (SI Appendix, Fig. S2C). These data indicate that UDP-
GalNAzMe is a viable substrate for GalNAc-Ts to generate
azide-tagged O-GalNAc glycans.
Labeling the Cellular O-GalNAc Glycome. We then opted to enable
biosynthesis of UDP-GalNAzMe 5 in the living cell. Our initial
attempts of using a per-acetylated precursor failed, as we did not
observe 5 in cell lysates by high-performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-
PAD). This was in line with previous findings on the low pro-
miscuity of both endogenous biosynthetic enzymes GALK2 and
AGX1 toward chemically modified substrate analogs (17, 26, 34).
Mutants of AGX1 with enlarged active sites have been used by us
and Yu et al. (35) to successfully transform analogs of GlcNAc-1-
phosphate or GalNAc-1-phosphate into the corresponding UDP
sugars and bypass the GALK2 phosphorylation step (Fig. 1A)
(26). We thus synthesized a caged, membrane-permissive version
of GalNAzMe-1-phosphate 11 (Fig. 2A) (26) and equipped cells
with the capacity to biosynthesize UDP-GalNAzMe 5 (Fig. 1A).
We transfected HEK293T cells with single and double mutants of
the AGX1 active site residues Phe381 and Phe383 (Fig. 2A).
Feeding these cells with caged GalNAzMe-1-phosphate 11 led to a
peak corresponding to UDP-GalNAzMe 5 only when AGX1F383A
termed “mut-AGX1” (26) was present (Fig. 2A and SI Appendix,
Fig. S2B). This result was somewhat surprising in the context of
our previous finding that both AGX1F383A and AGX1F383G ac-
cepted a different chemically modified GalNAc-1-phosphate an-
alog (26). When UDP-GalNAzMe 5 was biosynthesized from
precursor 11, we never observed a peak with the retention time of
UDP-GlcNAzMe in two different cell lines (SI Appendix, Fig.
S2B). As a control, Ac4GalNAz feeding generated an approximate
3:8 equilibrium between UDP-GalNAz and UDP-GlcNAz even
without overexpression of AGX1 (Fig. 2A) (15). Collectively, these
data indicate that UDP-GalNAzMe 5 can be biosynthesized by mut-
AGX1 in living cells and is not epimerized by endogenous GALE.
We next assessed incorporation of GalNAzMe into cell sur-
face glycans. K-562 cells stably transfected with WT- or mut-
AGX1 were treated with caged GalNAzMe-1-phosphate 11,
Ac4GalNAz, or dimethyl sulfoxide (DMSO). Azide-containing
glycans on the surface of living cells were reacted with click-
able (by CuAAC or SPAAC) fluorophores and visualized by flow
cytometry or in-gel fluorescence imaging (Fig. 2 C–E) (13, 14).
Caged GalNAzMe-1-phosphate 11 exhibited dose- (Fig. 2C) and
time-dependent (SI Appendix, Fig. S3A) incorporation when cells
expressed mut-AGX1 but little incorporation in the presence of
WT-AGX1. Our data confirmed that UDP-GalNAzMe 5 must
be biosynthesized for fluorescent labeling to be detectable,
thereby ruling out nonspecific incorporation (36).
To elucidate the nature of azide-labeled cell surface glycans,
we compared the glycoprotein patterns labeled with GalNAz or
GalNAzMe by in-gel fluorescence. Feeding caged GalNAzMe-1-
phosphate 11 labeled a subset of the glycoprotein bands of
Ac4GalNAz (Fig. 2D), consistent with UDP-GalNAz 2 being
epimerized and entering GlcNAc-containing glycans. The same
behavior was observed in HepG2 cells (SI Appendix, Fig. S3B).
To assess labeling specificity, we also tested glycoprotein suscep-
tibility toward hydrolytic enzymes. We treated samples with the
mucinase StcE that specifically digests highly O-GalNAcylated
mucin domains or with sialidase that removes sialic acid from
glycoconjugates (37). Following StcE treatment, the most intense
bands labeled by both caged GalNAzMe-1-phosphate 11 and
Ac4GalNAz feeding had disappeared. The remaining band pat-
tern was much more complex in samples from Ac4GalNAz- than
from 11-fed cells (Fig. 2D). Flow cytometry confirmed that StcE
treatment decreased the overall labeling intensity of cells fed with
caged GalNAzMe-1-phosphate 11, Ac4GalNAz, or the azide-
tagged sialic acid precursor Ac4ManNAz (Fig. 2E). In contrast,
sialidase treatment led to an increase of labeling with both 11 and
Ac4GalNAz, presumably due to better accessibility by the click
reagents to the azide-tagged glycan structures without sialic acid.
The labeling intensity after feeding Ac4ManNAz was reduced by
sialidase treatment (Fig. 2E and SI Appendix, Fig. S3C). These
data suggest that GalNAzMe enters the mucin subset of GalNAz-
modified glycoproteins, and neither GalNAc derivative substan-
tially enters the sialic acid pool. We further found that both
Ac4GalNAz and GalNAzMe-1-phosphate 11 exhibited a similar
small growth reduction when fed repeatedly to K-562 cells (SI
Appendix, Fig. S3D).
While characterizing the activity of mut-AGX1 in living cells,
we found that the biosynthesis of both UDP-GalNAz and UDP-
GlcNAz from per-acetylated precursors was enhanced in the
presence of mut-AGX1 over WT-AGX1, leading to a severalfold
increase of cell surface labeling (SI Appendix, Fig. S4). In con-
trast, Ac4ManNAz-induced labeling was not affected, indicating
that mut-AGX1 is a versatile enzyme to facilitate GlcNAc- and
GalNAc-based metabolic labeling.
We next confirmed that GalNAzMe specifically enters O-GalNAc
glycosylation in living cells. We used mut-AGX1–transfected GALE-
KO K-562 cells or the corresponding control cells carrying a non-
coding sgRNA (26). In GALE-KO cells, GalNAz and GalNAzMe
should enter the exact same subset of glycans. In cells expressing












































GALE, UDP-GalNAz 2 should be epimerized and label more cel-
lular glycoproteins than UDP-GalNAzMe 5 (Fig. 3A). We first pro-
filed UDP-sugar levels by HPAEC-PAD in azido sugar-fed cells.
As predicted, UDP-GalNAz 2 and UDP-GlcNAz (from the
precursor Ac4GlcNAz) were not epimerized in GALE-KO cells
while epimerization occurred in GALE-expressing cells (Fig. 3B)
(26). UDP-GalNAzMe 5 levels were equal in both cell lines fed
with 11, and no epimerization was observed irrespective of the
presence of GALE. To confirm that these azido sugars enter
glycans, we performed a competition experiment in GALE-KO
cells by flow cytometry. We used the free sugars GalNAc and
GlcNAc to compete with metabolic labeling and SPAAC to
fluorescently detect azide-containing glycoproteins (Fig. 3 C and
D). Cells fed with both Ac4GalNAz and caged GalNAzMe-1-
phosphate 11 lost fluorescence intensity in the presence of in-
creasing concentrations of GalNAc, while only Ac4GlcNAz la-
beling was abrogated by an excess of GlcNAc (Fig. 3C).
We then assessed glycosylation of discrete bona fide
O-GalNAc–glycosylated or N-glycosylated proteins with azido
sugars. CD43, the most abundant cell surface glycoprotein on K-
562 cells, is heavily O-GalNAc glycosylated (38). In contrast,
CD47 contains six potential N-glycosylation sites and no pre-
dicted O-GalNAc glycans (39). We fed normal or CD47-
GFP–overexpressing K-562 cells with caged GalNAzMe-1-
phosphate 11, Ac4GalNAz, Ac4GlcNAz, or DMSO. Cell lysis
and subsequent conjugation with an azide-reactive 10-kDa
polyethylene glycol (PEG) chain by SPAAC led to a mass shift
visible by western blot whenever the azidosugar was incorporated
(40, 41). We observed a clear mass shift in CD43 after feeding
GalNAzMe-1-phosphate 11, Ac4GalNAz, or Ac4GlcNAz to WT
K-562 cells (Fig. 3D). The mass shift induced by GalNAzMe-1-
phosphate 11 was only observed when mut-AGX1 was expressed.
The Ac4GlcNAz-induced mass shift was lost in GALE-KO cells,
confirming that these cells could not generate UDP-GalNAz from
UDP-GlcNAz (SI Appendix, Fig. S5A). A mass shift in overexpressed
CD47-GFP was only seen in lysates of cells fed with Ac4GalNAz
or Ac4GlcNAz but not with caged GalNAzMe-1-phosphate 11
Fig. 2. GalNAzMe can be used to label the cell surface glycoproteome. (A) Biosynthesis of UDP-GalNAzMe by mut-AGX1. HEK293T cells were transiently
transfected with plasmids encoding for different AGX1 constructs or left nontransfected. Cells were fed with 200 μM compound 11 or Ac4GalNAz, and cell
lysates were analyzed by HPAEC-PAD. Inset, active site of WT-AGX1. (B) Cell surface labeling workflow using either CuAAC or SPAAC. (C) Dose dependence of
GalNAzMe labeling by K-562 cells stably expressing WT-AGX1 or mut-AGX1, as assessed by flow cytometry. Data are mean ± SD from three independent
replicates. (D) Cell surface mucin labeling by GalNAzMe and GalNAz. K-562 cells stably expressing WT-AGX1 or mut-AGX1 were fed with DMSO, 3 μM
Ac4GalNAz, or 100 μM compound 11 and treated with CF680-alkyne as outlined in B. Cells were optionally treated with 50 nM StcE before the click reaction.
Data are from one representative of two independent experiments. (E) Cells were treated with either StcE or Vibrio cholerae sialidase and then treated with
MBTM 488-DIBAC as outlined in B, and glycosylation was assessed by flow cytometry. Data are mean + SD of three independent experiments. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; FLAG, DYKDDDDK epitope tag; n.t., non-transfected; PDB, protein database identifier.
































(Fig. 3D). CD43 was labeled by 11 in the same cell line (SI
Appendix, Fig. S5B).
In-gel fluorescence confirmed that caged GalNAzMe-1-phos-
phate 11 and Ac4GalNAz led to identical band patterns of gly-
coproteins in GALE-KO cells (Fig. 3E). Strikingly, Ac4GlcNAz
feeding of GALE-KO cells led to a diffuse pattern of low-
intensity glycoprotein bands that resembled the background
bands of WT cells fed with Ac4GalNAz. Furthermore, the Gal-
NAzMe labeling pattern was not influenced by the presence or
absence of GALE. Taken together, these data indicate that
UDP-GalNAzMe 5 exclusively enters O-GalNAc glycans, while
UDP-GalNAz 2 is epimerized and additionally enters GlcNAc-
containing glycans. Notably, a 3- to 5-kDa difference in molec-
ular mass was seen between proteins labeled with Ac4GalNAz in
WT cells on one hand and either GALE-KO cells fed with
Ac4GalNAz or any cell line fed with caged GalNAzMe-1-phos-
phate 11 on the other hand (Fig. 3E). We assume that the weight
shift may be due to a difference in either glycan elaboration or
glycosylation site occupancy and note that this labeling behavior
is further validation that GalNAzMe in WT cells mimics the
attributes of GalNAz in GALE-KO cells.
To further structurally confirm that UDP-GalNAzMe 5 is not
accepted as a substrate by GALE but is accepted by GalNAc-Ts such
as GalNAc-T2, we computationally docked UDP-GalNAzMe into
the active sites of both enzymes. We found that the energy-minimized
conformation would place the 2-azidopropioamide side chain closer
(2.7 and 2.9 Å) than the N–C van der Waals radius of 3.3 Å from
nearby amino acid side chains in GALE (SI Appendix, Fig. S5C). In
contrast, UDP-GalNAzMe was accommodated in GalNAc-T2 with-
out such steric clashes.
GalNAzMe as an O-GalNAc–Specific Reporter Molecule. We obtained
MS evidence for incorporation of GalNAzMe into O-GalNAc
glycans. We first confirmed that global cell surface N- and
O-glycome profiles of K-562 cells fed with either caged Gal-
NAzMe-1-phosphate 11 or Ac4GalNAz did not differ substan-
tially (SI Appendix, Fig. S6). We then used chemical MS
glycoproteomics to assess the incorporation of GalNAzMe into
cell surface O-GalNAc glycans. Biotin-containing, acid-cleavable
alkynyl probe 12 served to enrich azide-containing glycoproteins
from the de–N-glycosylated secretome of HepG2 cells (SI Ap-
pendix, Fig. S7A). Samples were digested with Lysyl endopepti-
dase (LysC) after enrichment on Lys-dimethylated Neutravidin
beads with enhanced LysC resistance (42). Following glycopep-
tide release, tandem MS was used to sequence glycopeptides.
Higher-energy collisional dissociation served to characterize
glycan-derived ions, and spectra containing the ions for GalNAzMe
(343.1617 mass-to-charge ratio [m/z]) and GalNAz (329.1461 m/z)
triggered corresponding electron-transfer dissociation to sequence
peptides (26). All spectra were manually validated. Both GalNAzMe
and GalNAz were found as peptide-proximal residues in O-GalNAc
glycans (Fig. 4A, Dataset S1, and SI Appendix, Fig. S7 B and C) and
were extended by the downstream glycosylation machinery (43).
For instance, biosynthetic considerations allowed the assign-
ment of the disaccharide β-Gal-(1–3)-α-GalNAzMe-(Thr*) on the
Fig. 3. UDP-GalNAzMe is not epimerized and labeled a subset of the UDP-
GalNAz–modified glycoproteome. (A) Schematic of the pathways probed
herein. Both GalNAc-1-phosphate analog 11 and Ac4GalNAz are precursors
for O-GalNAc glycosylation. (B) UDP-GalNAzMe is not epimerized in the
living cell, while UDP-GalNAz and UDP-GlcNAz are epimerized. K-562 GALE-
KO and control cells stably transfected with mut-AGX1 were treated with
200 μM compound 11, Ac4GalNAz, DMSO, or Ac4GlcNAz, and UDP-sugar
biosynthesis was assessed by HPAEC-PAD. (C) GALE-KO cells were treated
with 100 μM compound 11, 10 μM Ac4GalNAz, or 10 μM Ac4GlcNAz and
supplemented with GalNAc or GlcNAc in the indicated concentrations. Cell
surface labeling was assessed by flow cytometry after SPAAC using MBTM
488-DIBAC, and fluorescence intensity was normalized to DMSO-treated
cells. Data are mean + SD from three independent experiments. (D) K-562
cells stably expressing WT- or mut-AGX1 were fed with DMSO, 100 μM com-
pound 11, 3 μM Ac4GalNAz, or 8 μM Ac4GlcNAz and subjected to PEG mass
tagging. K-562 cells stably expressing WT- or mut-AGX1 and GFP::CD47 were
fed with DMSO, 100 μM compound 11, 3 μM Ac4GalNAz, or 8 μM Ac4GlcNAz
and subjected to PEG mass tagging. (E) Cells were fed with compounds as in
D, live cells were treated with CF680-alkyne under CuAAC conditions, and
proteins in cell lysates were visualized by in-gel fluorescence. Ac4ManNAz
(0.5 μM) was used as a positive control. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; FLAG, DYKDDDDK epitope tag; MFI, mean fluorescence
intensity; C, control-sgRNA.












































glycopeptide TTPPT*TATPIR of human fibronectin, along with other
glycoforms and even a diglycosylated peptide TTPPT*T*ATPIR
(Dataset S1). DMSO feeding did not lead to discernible signal.
Taken together, GalNAzMe is a substitute of the peptide-proximal
O-GalNAc residue.
We then probed the potential of GalNAzMe as an
O-GalNAc–specific reporter molecule in methods of modern
glycobiology. Superresolution microscopy was used to image the
glycocalyx on mut-AGX1–transfected K-562 cells fed with caged
GalNAzMe-1-phosphate 11 and Ac4GalNAz (Fig. 4B). Recently
described mucin-covered tubules on these cells were clearly visible
with both reagents, reflecting the fact that mucins are the most
abundant glycoproteins in this cell line (44).
We next employed GalNAzMe-1-phosphate 11 as a reporter
in a fluorescence-based genome-wide CRISPR-KO screen to
investigate the genetic factors of glycan biosynthesis (Fig. 4C and
Datasets S2 and S3). Specifically, we hypothesized that Gal-
NAzMe labeling would be sensitive to knockout (KO) of genes
that mediate cell surface O-glycan presentation, such as mucins.
GalNAz labeling, conversely, is likely to be reduced by KO of a
wider array of glycogenes. We thus conducted paired genome-
wide KO screens to reveal, in an unbiased manner, the key genes
that are essential for cell surface incorporation of the two met-
abolic labels. K-562 cells stably expressing Streptococcus pyogenes
Cas9 and mut-AGX1 were transduced with a lentiviral plasmid
library encoding 212,821 sgRNAs targeting 20,549 genes (10
sgRNAs per gene) (45). Cells were subsequently fed with caged
GalNAzMe-1-phosphate 11 or Ac4GalNAz and treated with the
fluorophore MBTM 488-Azadibenzylcyclooctyne (DIBAC) under
SPAAC conditions. Cells with the 15% lowest fluorescence in-
tensity were collected via fluorescence-activated cell sorting
(FACS). Changes in sgRNA frequency were determined by deep
sequencing and calculated relative to a nontreated control
sample. Using the multiplicity of sgRNAs targeting the same
gene, a statistical score and effect size could be derived for each
gene using the Cas9 high-Throughput maximum Likelihood
Estimator (casTLE) scoring system (46). The gene encoding for
the GalNAc 1-kinase GALK2 was essential for labeling with
Ac4GalNAz but not significant for labeling with caged Gal-
NAzMe-1-phosphate 11 (Fig. 4C and SI Appendix, Fig. S7 D and
E). This finding is consistent with the use of caged sugar-1-
phosphates, such as 11, to bypass the GALK2 step (26, 35).
Strikingly, targeting the genes encoding for dolichol kinase
DOLK and the mannosyltransferases ALG1 and ALG2 in the
N-glycan biosynthesis pathway was detrimental for Ac4GalNAz
labeling. In contrast, the same genes were not essential for la-
beling with caged GalNAzMe-1-phosphate 11, consistent with
our findings that GalNAzMe does not label N-glycans. KO of
UDP-glucuronic acid decarboxylase (UXS1), an early enzyme in
the biosynthesis of glycosaminoglycans such as heparin sulfate
(HS), was also detrimental for GalNAz but not GalNAzMe la-
beling (Fig. 4C and SI Appendix, Fig. S7 D and E). UDP-GalNAz
1 may enter HS after epimerization to UDP-GlcNAz that can be
used as a substrate by the HS polymerases EXT1/EXT2 (47).
Conversely, one of the top genes associated with GalNAzMe
signal was SPN encoding for CD43, consistent with CD43 being
Fig. 4. GalNAzMe is a reporter for the biology of O-GalNAc glycosylation. (A) GalNAzMe as a reporter in MS-based glycoproteomics of the HepG2 secretome.
Exemplary mass spectra from GalNAzMe-containing glycopeptides. (B) GalNAzMe as a reporter for superresolution microscopy using K562 cells for labeling
with GalNAzMe or GalNAz and CuAAC with Alexa Fluor 647 alkyne as a visualization strategy. (Scale bar, 10 μm.). Insets, whole cell images. (C) GalNAzMe as a
reporter for a genome-wide CRISPR-KO screen in K-562 cells stably transduced with Cas9 and mut-AGX1 followed by feeding with Ac4GalNAz or compound
11, labeled by MBTM 488-DIBAC, and subjected to FACS to sort the bottom 15% fluorescent cells and sequence sgRNAs. Effects on selected glycogenes are
shown—color depicts the relative phenotype (positive/red: enriched in the low-fluorescence population; negative/blue: depleted in the low-fluorescence
bottom population), while asterisks depict false discovery rate (FDR) as a measure of statistical significance from two independent experiments. ETD, electron-
transfer dissociation; HCD, higher-energy collisional dissociation; ns, nonsignificant. *FDR 5%; **FDR 2%.
































glycosylated with GalNAzMe (Fig. 3D). CD43 KO was not det-
rimental for GalNAz fluorescence, indicating that other glycans,
including N-glycans, may compensate for the loss of CD43 under
these conditions. Loss of several genes that encode for glycan
biosynthetic determinants led to a net increase of fluorescence
intensity. This was indicated by a depletion of sgRNAs targeting
those genes in the sorted pool of 15% cells with lowest fluores-
cent labeling. These genes were generally associated with the
elaboration of glycans that, upon loss, probably led to better ac-
cessibility of azido sugars to the click reagents. For instance, the
chaperone C1GALTC1 is implicated in elaborating O-GalNAc
glycans using UDP-galactose, a metabolite that is, in turn, shut-
tled into the Golgi compartment by the transporter SLC35A2. KO
of both C1GALTC1and SLC35A2 led to deenrichment in the low-
labeling pool (Fig. 4C). Loss of GALE generally leads to a de-
crease of cellular UDP-GalNAc levels (26). As a consequence,
azide-tagged UDP-GalNAc analogs might be preferentially used
as substrates by GalNAc-Ts, explaining the concomitant increase
in fluorescence labeling (26). Furthermore, impaired sialic acid
biosynthesis by KO of the transporter SLC35A1 or the enzymes
NANS, GNE, and CMAS led to an increase of labeling with both
11 and Ac4GalNAz. This finding is in line with our result that
sialidase treatment of the cell surface increased the labeling in-
tensity of a clickable fluorophore (SI Appendix, Fig. S3C). Taken
together, these results validate GalNAzMe as a potent reporter
tool for further genetic profiling of O-GalNAc glycan biosynthesis.
BH-Mediated Increase of GalNAzMe Labeling by GalNAc-T2.Although
UDP-GalNAzMe 5 can be biosynthesized by mut-AGX1 and
enter O-GalNAc glycans, we consistently observed moderate
glycoprotein labeling efficiency compared with UDP-GalNAz 2.
While it is not surprising that increasing specificity of a reagent
impairs its efficiency, we tested whether GalNAzMe signal could
be enhanced by a chemical genetics approach. One of the factors
hampering signal was low acceptance by WT-GalNAc-Ts (SI
Appendix, Fig. S2A). We therefore opted to develop a pro-
grammable labeling boost by making use of our BH-GalNAc-T
technology (25, 26). We employed the GalNAc-T2I253A/L310A
double mutant (BH-T2) that exhibits a twofold increased activity
with UDP-GalNAzMe 5 compared with the WT enzyme but
displays lower activity with UDP-GalNAc 1 and UDP-GalNAz 2
(Fig. 5A) (25, 26). Labeling of membrane proteins with UDP-
GalNAzMe 5 by WT-T2 in vitro was competed out by increasing
concentrations of UDP-GalNAc 1 (Fig. 5B). In contrast, labeling
with 5 by BH-T2 could not be competed out with UDP-GalNAc
1. Labeling with UDP-GalNAz 2 was competed out by an excess
of UDP-GalNAc 1 in the presence of both WT- and BH-T2. The
presence of BH-T2 also led to a marked increase of glycoprotein
labeling with caged GalNAzMe-1-phosphate 11 compared with
WT-T2 in the living cell, as observed by in-gel fluorescence ex-
periments (Fig. 5C). In contrast, Ac4GalNAz labeling was un-
changed. These data indicate that O-GalNAc labeling by
GalNAzMe can be enhanced by BH-engineered BH-T2.
Labeling the O-GalNAc Glycome in Organoids. We then turned to
investigating O-GalNAc glycosylation in a multicellular model
system. Intestinal organoids are instrumental in understanding
some of the key concepts of bowel cancer formation as well
as normal gut development and homeostasis (48–52). Produc-
tion of O-GalNAc glycans in such systems is often probed
by either backbone-directed antibodies or lectins (53, 54). We
used GalNAzMe as an O-GalNAc glycan detection tool that is
independent of both protein backbone and glycan capping
but reports on the peptide-proximal, invariant GalNAc moi-
ety. We stably transfected murine intestinal organoids with
both mut-AGX1 and BH-T2 and fed either caged GalNAzMe-
1-phosphate 11 or Ac4GalNAz (55). Treatment with a clickable
biotin-alkyne under CuAAC conditions and fluorescently labeled
streptavidin indicated a striking difference in labeling patterns
between the two azido sugars by confocal microscopy (Fig. 5D).
Ac4GalNAz labeling was generally found on all cell surfaces,
including intercellular boundaries. In contrast, caged Gal-
NAzMe-1-phosphate 11 labeling was focused on a subset of cells.
Our labeling strategy was topologically restricted to the baso-
lateral (nonluminal) side of the organoids, and GalNAzMe la-
beling was broadly localized to both cell surface and a subcortical
space. Streptavidin signal was absent in both nontransfected, 11-
fed organoids as well as transfected, DMSO-fed organoids, ex-
cluding nonspecific labeling (SI Appendix, Fig. S8). We con-
cluded that caged GalNAzMe-1-phosphate 11 is a valuable
labeling tool with an O-GalNAc glycan precision that is not seen
in the conventional reagent Ac4GalNAz.
Discussion
Efforts to map the systems biology of organisms, tissues, and
single cells demand specific and curated reporter tools. The ca-
pacity to accurately report on the presence and dynamics of in-
dividual glycan types is essential to understanding how glycans
Fig. 5. An engineered BH-T2 double mutant enhances GalNAzMe labeling.
(A) The principle of BH engineering using engineered GalNAc-T2 (BH-T2)
that preferentially accommodates UDP-GalNAzMe. (B) In vitro glycosylation
using WT- or BH-T2 as enzyme sources. UDP-GalNAz 2 and UDP-GalNAzMe 5
were used as substrates, and UDP-GalNAc 1 was used as a competitor at
different concentrations. Azide-labeled glycoproteins were visualized as in
Fig. 2B. Data are from one representative of two independent replicates. (C)
Live cell surface glycosylation by K-562 cells stably transfected with mut-
AGX1 and WT- or BH-T2 and fed with DMSO, 50 μM compound 11, or 3
μM Ac4GalNAz. Data are from one representative of two independent rep-
licates. (D) Glycosylation in intestinal organoids transfected with mut-AGX1
and BH-T2. Organoids were fed with 50 μM compound 11 or 1.5 μM
Ac4GalNAz, fixed, and treated with biotin alkyne under CuAAC conditions
followed by streptavidin Alexa Fluor 647 staining. Data are from one rep-
resentative of two independent experiments and shown as grayscale images
for each channel and a color merge image of all three channels. (Scale bar,
100 μm.) Insets, magnifications. DAPI, 4′,6-diamidino-2-phenylindole.












































impact biological processes. Protein-based reporter reagents
have enabled the study of glycobiology but rarely probe non-
accessible glycan core structures. Thus far, the forays made into
developing chemical tools have yielded an arsenal of monosac-
charide analogs: for instance, of ManNAc/Sia (8, 56–58),
GlcNAc (18–20, 35), Fuc (59), Gal (60, 61), and GalNAc/
GlcNAc (10, 15, 17, 62, 63). Probes are typically selected based
on their labeling intensity, which in turn, is often a function of
poor glycan specificity. The usefulness of these probes in bio-
logical applications is therefore limited, especially in the case of
GalNAc analogs that can be epimerized to the corresponding
UDP-GlcNAc analogs. UDP-GlcNAc is not only thermody-
namically more stable than UDP-GalNAc but also used by a
much more diverse set of glycosyltransferases (www.cazy.org)
(15). The possibility to interconvert derivatives of both metab-
olites is therefore likely to create a GlcNAc-dependent labeling
background if GalNAc is actually to be studied. Here, a panel of
synthetic UDP-GalNAc analogs was essential to corroborate our
structure-based design of a GalNAc-specific metabolic labeling
reagent. GalNAzMe is a useful monosaccharide in a range of
biological applications, showcased here by superresolution mi-
croscopy, chemical glycoproteomics, a genome-wide CRISPR-
KO screen, and imaging of intestinal organoids. Our approach to
study O-GalNAc glycosylation by metabolic labeling is compat-
ible with the presence of GALE, which is of particular impor-
tance for advanced model systems such as organoids that would
be difficult to establish in a GALE-KO background with pre-
dictable phenotypic perturbations (64). In line with a reciprocal
relationship between probe specificity and sensitivity, caged
GalNAzMe-1-phosphate 11 was associated with lower intensity
in fluorescent labeling experiments when compared with the less
specific reagent Ac4GalNAz. Our finding that GalNAzMe in-
corporation can be elevated by expressing a BH-engineered
GalNAc-T double mutant is therefore valuable, especially for
experiments in which high glycan labeling intensity is desired.
While cells need to be transfected to incorporate GalNAzMe,
this provides an additional control for background labeling in the
absence of mut-AGX1 and/or BH-GalNAc-Ts. Further, the use of
transposase-mediated transfection of both AGX1 and GalNAc-T
from the same vector renders our approach amenable to a wide
range of cell lines and even complex model systems such as
intestinal organoids. GalNAzMe is a precision tool that will prove
to be valuable in tackling important mucin-specific biological
questions.
Materials and Methods
Experimental details on expression and purification of GALE, in vitro epi-
merization, peptide glycosylation, plasmids, cell transfection, lysate labeling,
analysis of nucleotide-sugar biosynthesis, metabolic cell surface labeling,
growth assessment, flow cytometry and in-gel fluorescence, superresolution
microscopy, PEG mass tagging, genome-wide CRISPR-KO screen, click and
enrichment of HepG2 secretome glycoproteins, organoid culture and gen-
eration of stably overexpressing organoid lines, organoid labeling and im-
munofluorescence, and chemical synthesis can be found in SI Appendix. The
MS proteomics data have been deposited in the ProteomeXchange Con-
sortium via the Proteomics Identification Database (PRIDE) partner reposi-
tory with the dataset identifier PXD020648 (65).
Data Availability. Glycoproteomics data have been deposited in PRIDE Pro-
teomics database (dataset identifier no. PXD020648) and are accessible
under https://www.ebi.ac.uk/pride/archive/projects/PXD020648.
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